For global pharmaceutical companies, the perceived value of their drug pipeline is increasingly critical to their corporate reputation. For smaller life science businesses, discovering and developing new drugs - where time to profitability is longer than in almost any other industry, reputation is entirely dependent on the credibility of management, the strength of the drug pipeline and the sustainability of the business model. At De Facto we have a huge array of experience in brand-building communications – B2C, B2B and direct to stakeholder. We work with ambitious, ground-breaking companies to help them define the very essence of their brand, then manage the complexities of building its profile in this fluid and challenging marketplace. Our access to the media, the financial community, government bodies, thought leaders and regulators usually exceeds our clients’ expectations. De Facto’s team is committed to working with you as a true business partner and to building long-term relationships whether you are based in the UK, Europe or the U.S. View our life science and biotechnology case studies in this sector. To find out more about our capabilities, email us at biotech@defacto.com.
© 2007 Company Clients Practices Services News Contact